Praxis Precision Medicines Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
19analysts covering
FY Revenue (est.)
$876.9Knext fiscal year
FY EPS (est.)
-$13.94next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Expected Topline Results from Relutrigine EMERALD Study in Broad DEEs | 31 Dec 2026 |
| FDA PDUFA Target Action Date for Ulixacaltamide (Essential Tremor) | 29 Jan 2027 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly1.4BTarget: Sufficient to fund operations into 2028
Quarterly Research and Development (R&D) Expenses Quarterly78M
Quarterly General and Administrative (G&A) Expenses Quarterly27.9M
Watch Items
- FDA PDUFA Action Date for Relutrigine in SCN2A and SCN8A DEEsTrigger: September 27, 2026Action: Monitor FDA decision and prepare for immediate commercial launch if approved.
- FDA PDUFA Action Date for Ulixacaltamide in Essential TremorTrigger: January 29, 2027Action: Monitor FDA decision and advance commercial readiness activities.
- Vormatrigine Program Reassessment and POWER2 Trial StatusTrigger: Completion of detailed dataset review following POWER1 primary endpoint missAction: Determine potential modifications to trial design, dosing strategy, or overall development path.
- Relutrigine EMERALD Study Topline Results in Broad DEEsTrigger: Fourth Quarter of 2026 (Q4 2026)Action: Evaluate efficacy and safety data to support a potential supplemental NDA (sNDA) submission in 2027.
Research as of 2 Sep 2026